Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

Abstract • About • The 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Diabetes

  Free Subscription


01.12.2025

2 Am J Clin Nutr
1 Am J Manag Care
1 Biochem Biophys Res Commun
2 Diabet Med
3 Diabetes
1 Diabetes Care
9 Diabetes Obes Metab
7 Diabetologia
3 J Diabetes Complications
1 Kidney Int
2 Lancet
1 Metabolism
1 Nature
1 Nutr Metab (Lond)
2 Pediatr Diabetes
1 PLoS Med
1 PLoS One
1 Transplantation


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Nutr

  1. LI R, Xu K, Zhu K, Liu J, et al
    Healthful dietary patterns and risks of microvascular complications among individuals with type 2 diabetes: a prospective cohort study.
    Am J Clin Nutr. 2025 Nov 20:101088. doi: 10.1016/j.ajcnut.2025.
    PubMed         Abstract available

  2. IBSEN DB
    Steps toward better understanding the role of dietary intake on development of complications in people with type 2 diabetes.
    Am J Clin Nutr. 2025 Nov 20:101104. doi: 10.1016/j.ajcnut.2025.
    PubMed        


    Am J Manag Care

  3. BORRELLI EP, Saad P, Barnes NE, Beer I, et al
    Relationship between medication adherence and other Medicare star rating measures.
    Am J Manag Care. 2025;31:688-692.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  4. ZHAO J, Dong C, Qiu P, Lv X, et al
    The effect of Dapagliflozin on diabetic nephropathy through PRMT1-SIRT1-FoxO1 pathway-mediated autophagy.
    Biochem Biophys Res Commun. 2025;793:152999.
    PubMed         Abstract available


    Diabet Med

  5. BERTHON W, McGurnaghan SJ, Blackbourn LAK, Fernandes AAS, et al
    Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort.
    Diabet Med. 2025 Nov 28:e70179. doi: 10.1111/dme.70179.
    PubMed         Abstract available

  6. MAJSTOROVIC M, McGorm KJ, Wentworth JM, Couper JJ, et al
    Knowledge about paediatric screening and monitoring of early-stage type 1 diabetes: A qualitative exploration of healthcare professionals' perspectives and experiences.
    Diabet Med. 2025 Nov 24:e70178. doi: 10.1111/dme.70178.
    PubMed         Abstract available


    Diabetes

  7. WILSON CS, Stocks BT, Falk AC, Moore DJ, et al
    B Lymphocytes Impede Tregs to Erode Islet Tolerance in Type 1 Diabetes.
    Diabetes. 2025 Nov 25:db250241. doi: 10.2337/db25-0241.
    PubMed         Abstract available

  8. SHARP LN, Mirshahi UL, Colclough K, Hall TS, et al
    MODY Is Prevalent in Later-Onset Diabetes and Has Potential for Targeted Therapy but Is Challenging to Identify.
    Diabetes. 2025 Nov 25:db250545. doi: 10.2337/db25-0545.
    PubMed         Abstract available

  9. MITTENDORFER B, Patterson BW, Eagon JC, Yoshino M, et al
    Effects of Marked Weight Loss Induced by Gastric Bypass Surgery or Low-Calorie Diet Alone on Postprandial Glucose Disposal in Type 2 Diabetes.
    Diabetes. 2025 Nov 26:db250737. doi: 10.2337/db25-0737.
    PubMed         Abstract available


    Diabetes Care

  10. SANTOS-PARDO I, Andersson Franko M, Hofmann R, Nystrom T, et al
    Coronary Stent Failure in Patients With Diabetes: A Nationwide Observational Study From SWEDEHEART.
    Diabetes Care. 2025 Nov 27:dc251624. doi: 10.2337/dc25-1624.
    PubMed         Abstract available


    Diabetes Obes Metab

  11. LEWIS GA, Hughes DM, Irving G, Wilding J, et al
    Diabetes self-management education and its association with hospital admissions and premature mortality: A scoping review and meta-analysis.
    Diabetes Obes Metab. 2025 Nov 24. doi: 10.1111/dom.70296.
    PubMed         Abstract available

  12. ERIKSSON JW, Fanni G, Lundqvist MH, Jansson S, et al
    SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications.
    Diabetes Obes Metab. 2025 Nov 28. doi: 10.1111/dom.70320.
    PubMed         Abstract available

  13. EDD S, Laron-Hirsch M, Castaneda J, van den Heuvel T, et al
    A narrative review of meal management with the MiniMed 780G system: Evolution of dietary management in type 1 diabetes.
    Diabetes Obes Metab. 2025 Nov 28. doi: 10.1111/dom.70310.
    PubMed         Abstract available

  14. ELBADAWI H, Albalkhi N, Al Kadhim I, Elsadig A, et al
    PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.
    Diabetes Obes Metab. 2025 Nov 27. doi: 10.1111/dom.70317.
    PubMed         Abstract available

  15. HAN G, Zhang X, Ye Y, Wang C, et al
    Cost-effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA(1c).
    Diabetes Obes Metab. 2025 Nov 27. doi: 10.1111/dom.70333.
    PubMed         Abstract available

  16. CUNNINGHAM H, Apostolopoulos J, Ngan J, Jones H, et al
    Feasibility study of a combined insulin-delivery and glucose sensor system worn over 7 days in persons with type 1 diabetes.
    Diabetes Obes Metab. 2025 Nov 25. doi: 10.1111/dom.70331.
    PubMed         Abstract available

  17. LI Q, Li X, Bi Y, Lu J, et al
    Sensory network dysregulation in type 2 diabetes: Linking olfactory, visual, and cognitive function.
    Diabetes Obes Metab. 2025 Nov 25. doi: 10.1111/dom.70309.
    PubMed         Abstract available

  18. IWAMOTO Y, Iwamoto H, Kimura T, Kubo M, et al
    Correlation between diabetes complications severity index and actual complication severity and diabetic medication in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Nov 25. doi: 10.1111/dom.70321.
    PubMed        

  19. WINN M, Pauleck S, Richardson S, Viskochil R, et al
    New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study.
    Diabetes Obes Metab. 2025 Nov 24:10.1111/dom.70311. doi: 10.1111/dom.70311.
    PubMed         Abstract available


    Diabetologia

  20. MAYNARD AG, Bhardwaj R, Jones TR, Claussnitzer M, et al
    Bridging the variant-to-function gap in type 2 diabetes: advances and challenges.
    Diabetologia. 2025 Nov 22. doi: 10.1007/s00125-025-06600.
    PubMed         Abstract available

  21. TRIMBLE ER, Phillips DIW, Balcha SA
    From malnutrition-related diabetes mellitus to 'type 5 diabetes': phenotypic variation, not reclassification. Reply to Gupta L, Misra A [letter].
    Diabetologia. 2025 Nov 22. doi: 10.1007/s00125-025-06606.
    PubMed        

  22. BOLDISON J, Leete P, Robinson EJ, Powell W, et al
    CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.
    Diabetologia. 2025 Nov 22. doi: 10.1007/s00125-025-06608.
    PubMed         Abstract available

  23. CHO SH, Kim S, Oh R, Kim JY, et al
    High incidence of eating disorders in individuals with type 2 diabetes and their association with cardiovascular and mortality risks.
    Diabetologia. 2025 Nov 26. doi: 10.1007/s00125-025-06615.
    PubMed         Abstract available

  24. BANGSHAAB M, Bengtsen MB, Smedegaard S, Sondergaard E, et al
    Ketone supplementation dose-dependently lowers postprandial blood glucose, lipid and ghrelin levels in individuals with type 2 diabetes: a randomised crossover study.
    Diabetologia. 2025 Nov 28. doi: 10.1007/s00125-025-06614.
    PubMed         Abstract available

  25. MATSUI S, Yamamoto T, Takabatake Y, Takahashi A, et al
    Defective autophagy and AMPK inactivation drive ferroptosis in diabetic kidney disease.
    Diabetologia. 2025 Nov 28. doi: 10.1007/s00125-025-06612.
    PubMed         Abstract available

  26. HIGHTON PJ, Funnell MP, Gupta P, Zaccardi F, et al
    Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes.
    Diabetologia. 2025 Nov 28. doi: 10.1007/s00125-025-06617.
    PubMed         Abstract available


    J Diabetes Complications

  27. KATAYAMA S, Anker SD, Zhu D, Kim S, et al
    Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: A FIDELITY analysis by baseline kidney function.
    J Diabetes Complications. 2025;40:109213.
    PubMed         Abstract available

  28. MEDENICA S, Abazovic D, Vukovic J, Vojinovic T, et al
    Regenerative medicine approaches for treating diabetes: Current advances and future directions.
    J Diabetes Complications. 2025;40:109232.
    PubMed         Abstract available

  29. ORTIZ-SELLER A, Real JT, Morcillo E, Ortiz JL, et al
    Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials.
    J Diabetes Complications. 2025;40:109234.
    PubMed         Abstract available


    Kidney Int

  30. WANG YH, Chang DY, Zhao YY, Chi-Wai Tang S, et al
    Mitochondrial protein TOMM7 alleviates diabetic kidney disease by regulating mitophagy via intracellular redistribution of phospholipase PLA2G6.
    Kidney Int. 2025 Nov 21:S0085-2538(25)00882-8. doi: 10.1016/j.kint.2025.
    PubMed         Abstract available


    Lancet

  31. HEERSPINK HJL, Cardona JF, Jolly S, Pergola PE, et al
    Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
    Lancet. 2025 Nov 8:S0140-6736(25)02014-8. doi: 10.1016/S0140-6736(25)02014.
    PubMed         Abstract available

  32. HORN DB, Ryan DH, Kis SG, Alves B, et al
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
    Lancet. 2025 Nov 20:S0140-6736(25)02165-8. doi: 10.1016/S0140-6736(25)02165.
    PubMed         Abstract available


    Metabolism

  33. JINYI L, Xianguang D, Yuhan D, Haoyue H, et al
    Metabolic reprogramming in diabetic foot ulcers: mechanisms, therapeutic implications and future perspectives.
    Metabolism. 2025;175:156455.
    PubMed         Abstract available


    Nature

  34. ZAKHAROV PN, Chowdhury CS, Peterson OJ, Barron B, et al
    Efferocytic remodelling of pancreatic islet macrophages by limited beta-cell death.
    Nature. 2025 Oct 1. doi: 10.1038/s41586-025-09560.
    PubMed         Abstract available


    Nutr Metab (Lond)

  35. HONG L, Xia S, Chen N, Wang Z, et al
    Quercetin's regulation of glucose and lipid metabolism in gestational diabetes mellitus: role of the PCSK9/LDLR axis.
    Nutr Metab (Lond). 2025 Nov 24. doi: 10.1186/s12986-025-01048.
    PubMed        


    Pediatr Diabetes

  36. GUARINO S, Iafusco D, Di Sessa A, Tirelli P, et al
    Acidosis at Diagnosis of Type 1 Diabetes Mellitus: Relation With Kidney Function.
    Pediatr Diabetes. 2025;2025:3188571.
    PubMed         Abstract available

  37. AGENAS H, Odling M, Brorsson AL, Kull I, et al
    Diabetes Treatment Satisfaction Is Associated With Health-Related Quality of Life Among Parents and Children With Type 1 Diabetes.
    Pediatr Diabetes. 2025;2025:7760362.
    PubMed         Abstract available


    PLoS Med

  38. SYDNEY GI, Perdigoto AL, Herold KC
    Towards insulin independence in type 1 diabetes: Prospects for prevention and cure.
    PLoS Med. 2025;22:e1004813.
    PubMed         Abstract available


    PLoS One

  39. KHARDALI A
    Exploring the acceptability and attitude toward mobile health applications to aid self-management for people with type 2 diabetes mellitus in Saudi Arabia: A descriptive cross-sectional study.
    PLoS One. 2025;20:e0331314.
    PubMed         Abstract available


    Transplantation

  40. SEISSLER J, Figueiredo C, Kemter E, Klymiuk N, et al
    Anti-CTLA-4 Treatment Abrogates Co-stimulation Blockade-induced Acceptance of Transgenic Porcine Islets in Humanized Mice.
    Transplantation. 2025;109:e691-e696.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.